OncoMatch/Clinical Trials/NCT06684600
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Is NCT06684600 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dalpiciclib + Pyrotinib for esophageal squamous cell carcinoma.
Treatment: Dalpiciclib + Pyrotinib — The purpose of this study is to observe and evaluate the efficacy and safety of dalpiciclib combined with pyrotinib as second-line therapy in patients with advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic chemotherapy — first-line
Patients undergoing first-line systemic chemotherapy progression or intolerance (progress in maintenance therapy after first-line chemotherapy can also be included). Synchronous chemoradiotherapy for postoperative recurrence or metastasis is considered as first-line treatment; For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, Count it as a first-line treatment failure.
Cannot have received: radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy
Exception: eligible if last dose of anti-neoplastic medication was discontinued for ≥5 half-lives before the initial treatment
Prior radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy within 4 weeks of enrollment (eligible for enrollment if the last dose of anti-neoplastic medication was discontinued for ≥5 half-lives before the initial treatment); prior chemotherapy with nitrosoureas or mitomycin within 6 weeks of enrollment.
Cannot have received: chemotherapy with nitrosoureas or mitomycin
prior chemotherapy with nitrosoureas or mitomycin within 6 weeks of enrollment
Cannot have received: concurrent anti-neoplastic treatments
Concurrent administration of other anti-neoplastic treatments
Lab requirements
Blood counts
ANC≥1.5×10^9/L; PLT≥90×10^9/L; HB≥90g/L; ALB≥28g/L; APTT and INR ≤1.5 × ULN
Kidney function
plasma Cr ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min
Liver function
TBIL≤1.5 × ULN，ALT and AST ≤ 2.5ULN; if there is liver metastasis, ALT and AST ≤ 5ULN
The main organs function normally, that is, the following criteria are met: ANC≥1.5×10^9/L; PLT≥90×10^9/L; HB≥90g/L; ALB≥28g/L; TBIL≤1.5 × ULN，ALT and AST ≤ 2.5ULN; if there is liver metastasis, ALT and AST ≤ 5ULN; plasma Cr ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min; APTT and INR ≤1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06684600 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy, chemotherapy with nitrosoureas or mitomycin, concurrent anti-neoplastic treatments disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages